News | September 22, 2008

Invatec Opens U.S. Operations, Involved with FDA Brain Embolization Trial

September 23, 2008 – Italian-based Invatec today said at the annual VIVA (Vascular InterVentional Advances) conference that it has formally launched U.S. operations.

Located in Bethlehem, PA, the U.S. headquarters is responsible for the sales, marketing, clinical, regulatory and distribution of the company’s minimally-invasive diagnostic and therapeutic products. These products are used by interventional cardiologists, radiologists, vascular surgeons and other vascular specialists. The company also announced that it has appointed Jack Springer as president to lead U.S. operations.

Springer joins Invatec with more than 15 years of experience in endovascular therapies. He began his career in sales at Abbott Labs before joining Cordis Endovascular, where he worked for 12 years in positions of increasing responsibility leading to his appointment as General Manager for Cordis Endovascular. Most recently, he served as president and CEO at Neuromonics.

Invatec currently has a pivotal investigational device exemption clinical trial known as ARMOUR underway to assess the safety and efficacy of a proximal protection device, Mo.Ma, for use in carotid stenting with FDA approved carotid stents. Mo.Ma protects the brain from embolization by two highly compliant atraumatic balloons, blocking antegrade blood flow from the CCA (Common Carotid Artery) and retrograde blood flow from the ECA (External Carotid Artery). Importantly, protection is established before the critical phase of lesion crossing. Since its first introduction in the European market in 2001, the safety and performance of the Mo.Ma system has been reported in multiple clinical studies outside of the U.S., which also showed broad applicability in standard to complex cases with unmatched high level of technical success.

The study is enrolling patients at 25 investigational sites in the U.S. and Europe under the guidance and supervision of principal investigators Gary Ansel, M.D., Riverside Methodist Hospital, Columbus, OH, and L. Nelson Hopkins, M.D. University of Buffalo, Buffalo, NY.

Invatec, which offers 35 product families in 70 countries worldwide, offers a full PTA balloon product line and a thrombus management catheter available for sale in the U.S.

Invatec has also filed an IDE application seeking FDA permission to begin clinical investigations for an iliac stent. The company also plans to initiate several more clinical trials over the next three years.

For more information, visit www.invatec.us

Related Content

Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters | July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Roxwood Medical, MicroCross Catheter, full U.S. launch

Image courtesy of Roxwood Medical

Technology | Catheters | January 07, 2016
Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited...
Overlay Init